MacroGenics Inc (MGNX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.14 (+0.24%), Market cap $0.27B, 52-week low–high $1.19 ~ $4.25.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC)
Financial statements, price targets, institutional (13F) holdings and related news for MacroGenics Inc are updated in real time on BlackAll Trade.
MacroGenics Inc trades at $4.14 (+0.24%). Real-time quotes and charts are available on BlackAll Trade.
MacroGenics Inc has a market cap of about $0.27B.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The c